News
MolecularHealth Partners With SAP to Accelerate Decision-Support Software for Oncology Treatment
January 28, 2013
GenomeWeb | Udak Grace Thomas | Article
MOLECULARHEALTH is working with SAP to help it speed up a software solution it is developing to help oncologists make better treatment decisions for their patients. Read More…
MolecularHealth, Backed by SAP Founder, Debuts Software to Match Patients’ Genomes with Best Drugs
March 7, 2012
Xconomy | Arlene Weintraub | Article
When executives at medical software developer MolecularHealth were working on a new product for oncologists, they consulted with a cancer center that was grappling with an emerging trend: About 100 patients a year were paying for their own genomes to be sequenced. Read More…
Mining for Safety Mechanisms
March 5, 2012
BioCentury | Aaron Bouchie | Article
FDA has been quietly test-driving informatics platforms that include mechanism of action data to complement and augment the agency’s safety surveillance techniques. Most recently, FDA began evaluating MolecularHealth Inc.’s Molecular Analysis of Side Effects software system, which the company launched in January. Download PDF.
MASE gives FDA ‘Next Generation’ of Safety Assessment Technology
March 2, 2012
Modern Medicine | Formulary staff | Article
MolecularHealth announced a 5-year collaboration with FDA that will give FDA access to Molecular Analysis of Side Effects (MASE), the company’s flagship drug safety assessment tool. Read More…
Next-Generation Solutions for Guided Treatment Decision Support
February 29, 2012
Drug Discovery News | Article
MolecularHealth announces the commercialization and anticipated roll-out of two next-generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence so that safer, more effective drug choices can be made for patients. Read More…
New Venture for Personalized Medicine
February 27, 2012
Bio-IT World | February New Products | Article
MolecularHealth has announced the commercialization and planned roll-out of two next generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices for patients. Read More…
FDA: Steps Toward Quantitative Safety Assessment
February 18, 2012
PharmEx.com | Ben Comer | Article
A new collaboration will move FDA closer to predicting adverse events – before they happen – as part of the regulatory process
In an article published in Nature last June, FDA’s Darrell Abernethy, Lawrence Lesko and Janet Woodcock outlined the agency’s desire to incorporate “mechanism-based drug safety assessment and prediction” into the regulatory approval process. Read More…
FDA Evaluating MolecularHealth’s MASE for Analyzing Post-Market Drug Safety
February 15, 2012
GenomeWeb-Pharmacogenomics Reporter | Turna Ray | Article
Under a collaboration with personalized medicine-focused bioinformatics company MolecularHealth, the US Food and Drug Administration will evaluate software that will allow the agency to analyze and predict drug safety issues caused by a variety of factors, including pharmacogenomic interactions. Read More…
Alarmsignale im Durcheinander
February 15, 2012
Frankfurter Allgemeine Sonntagszeitung | von Sascha Karberg | Article
FDA Partners on More Precise Drug Safety Assessment Tool
February 15, 2012
Drug Industry Daily | Sarah Karlin | Article
The FDA may soon have a more precise tool to detect drug safety problems under a partnership with MolecularHealth to develop and improve detection software. Read More…